6 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 6 |
| Phase 2 | 1 | Terminated 1 |
Follow Vomiting: new trials by email Literature Review of Vomiting trials Research Report on Vomiting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis - Breast Cancer, Nausea | Phase 1 | Terminated | University of Southern California | 29 | 2012-09-04 | 2017-11-17 |
| TAP Block for Open Radical Prostatectomy. Normal saline via TAP catheters, Lidocaine via TAP catheters - Opioid Consumption, Incidence of Nausea and Vomiting | Phase 1 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 25 | 2010-08-01 | 2015-03-17 |
| Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain methadone hydrochloride, questionnaire administration, management of therapy complications - Nausea and Vomiting, Pain | Phase 1 | Terminated | NCIC Clinical Trials Group | 8 | 2010-06-17 | 2024-02-12 |
| A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron - Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 92 | 2009-02-05 | 2018-09-25 |
| Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy fosaprepitant dimeglumine, systemic chemotherapy, survey administration - Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Terminated | OHSU Knight Cancer Institute | 34 | 2008-08-01 | 2017-05-09 |
| Cyclophosphamide Drug Interaction Study In Cancer Patients Oral GW679769, IV Cyclophosphamide 500-700mg/m2 - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Terminated | GlaxoSmithKline | 25 | 2005-08-10 | 2017-11-17 |
Nausea (4) · Breast Neoplasms (1) · Pain (1) · Pain, Postoperative (1) · Sleep Wake Disorders (1)
Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Signs and Symptoms, Digestive (6) · Neurologic Manifestations (2) · Breast Diseases (1) · Mental Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Pain (1) · Pathologic Processes (1) · Postoperative Complications (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
fosaprepitant (3) · Aprepitant (1) · Cyclophosphamide (1) · Dexamethasone (1) · Granisetron (1) · Lidocaine (1) · Methadone (1) · Neoadjuvant Therapy (1) · Ondansetron (1) · Saline Solution (1) · casopitant (1)
GlaxoSmithKline (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Merck Sharp & Dohme LLC (1) · NCIC Clinical Trials Group (1) · OHSU Knight Cancer Institute (1) · University of Southern California (1)
United States (3) · Canada (2) · New Zealand (1) · Sweden (1)
Agustin Garcia (1) · Bruno Gagnon, MD, MSC (1) · Franco Carli, Professor (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Ray Viola (1)
P30CA069533 (1)